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Summary
Introduction: Hepatitis E virus (HEV) is an enterically transmitted acute viral hepatitis with the
highest incidence in Asia, Africa, the Middle East, and Central America. There are few published
data on the epidemiology of the infection in Iran. Hence, this study was carried out to evaluate
anti-HEV seroprevalence in Isfahan Province, Iran.
Methods: In 2005, a cross-sectional study of 816 subjects over 6 years of age from urban and rural
areas of Isfahan Province, selected using the multistage cluster sampling method, was under-
taken. Demographic data and blood samples were collected, and anti-HEV antibodies were
measured by ELISA method. The Chi-square test was used for statistical analysis and p < 0.05 was
considered significant.
Results: Of the study subjects, 428 were female (52.5%) and 388 were male (47.5%). The overall
anti-HEV seroprevalence rate was 3.8%. There was no significant difference in HEV seropositivity
between the subjects grouped according to gender (4.2% in females and 3.4% in males, p = 0.78),
household number ( p = 0.95), and area of residence (2.7% in rural and 4.1% in urban areas,
p = 0.09). HEV seroprevalence increased with age from 0.9% in children aged 6—9 years to 8.1% in
persons over 50 years old, without statistical differences ( p = 0.08). There were statistical
differences in HEV seropositivity in the different regions of Isfahan Province, with the highest
prevalence seen in Khomeini Shahr (13.3%; p < 0.001).
Conclusion: HEV seroprevalence in Isfahan Province is lower than that previously reported in other
parts of Iran and the Middle East area. More studies in other parts of Iran are needed to obtain a
prevalence map for creating preventional strategies.
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Viral hepatitis is a public health problem in several regions of
the world. Hepatitis E virus (HEV) appears to be the second
most frequent cause of enteric hepatitis after hepatitis A
virus infection. HEV results in acute hepatitis, which isPublished by Elsevier Ltd. All rights reserved.
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(from about 20% to 30%), especially during the third trimester
of pregnancy, as a result of fulminant liver disease.1 Recently,
the virus has been reclassified in the genus Hepevirus of the
family Hepeviridae.2 HEV is spread by focally contaminated
water and by blood transfusion in endemic areas, but person-
to-person transmission is uncommon. Avaccine against HEV is
not yet commercially available, and travelers to endemic
areas should engage in practices that may prevent infection
such as avoiding drinking water of unknown purity and eating
uncooked shellfish, fruits, or vegetables.3—5 High attack rates
are found in adults between 15 and 40 years of age. Second-
ary attack rates in susceptible household contacts are low
due to the lack of person-to-person transmission, and range
from 0.7% to 2.2%.6
The prevalence of antibodies to HEV (anti-HEV) has been
described for several populations, with levels as high as 40%
in India.7 Investigations show that HEV-mediated hepatitis is
a serious public health problem in developing countries of
Asia, the Middle East, and Africa, as well as in Mexico.2 In
much of Asia, HEV is the single most frequent cause of acute
hepatitis in adults, and in parts of the Middle East and North
Africa it is second only to hepatitis B. HEV endemicity in the
world is currently under investigation, and a more complete
picture of the worldwide distribution and seroprevalence of
HEV infections is emerging.8Figure 1 MaThe results of limited epidemiological studies in Iran have
implied regional differences in anti-HEV antibody seropreva-
lence rates and there are no documents on this subject in the
central and south areas of our country. Hence, the aim of this
study was to identify anti-HEV prevalence in the human
population of Isfahan Province, as a tourist area in Iran,
and its relationship with age, gender, education, household
numbers, and region, to support the implementation of
future strategies to improve national and international sur-
veillance.Methods and materials
In a cross-sectional survey in 2005, 816 samples from the
population of Isfahan Province aged over 6 years were col-
lected using the multistage cluster sampling method. Isfahan
is a large province in the center of Iran with a high level of
tourism, and about 79.3% of residents live in the urban areas.
This province is located southeast of Tehran and consists of 19
districts. Isfahan City is the center of Isfahan Province (Fig-
ures 1 and 2).
There were 41 clusters in each of 20 samples, from which,
according to the proportion of the population in rural and
urban areas, nine rural and 11 urban clusters were selected.
From each selected family, one subject in each age group wasp of Iran.
Figure 2 The conditional map of Isfahan Province in Iran.
Hepatitis E virus in Isfahan Province 69chosen randomly to be enrolled into the study. There were six
age groups: 6—9, 10—19, 20—29, 30—39, 40—49, and over 50
years.
The subjects were given detailed information about the
study, and written consent was obtained. They were asked
about their age, gender, area of residence, number in the
household, and education. A 5 ml venous blood sample was
drawn from each subject and transferred to the healthcare
center in less than 3 hours. Whole blood was centrifuged at
3000 rpm for 15 min and after serum isolation, was frozen by
Alicot method. Samples were then transferred to the Isfahan
Infectious Diseases and Tropical Medicine Research Center by
cold chain method and were stored at 70 8C until the anti-Table 1 Prevalence of anti-HEV based on demographic data in I
Conditions Anti-HEV
n
Gender Female 18
Male 13
Area of residence Urban 26
Rural 5
Household numbera 1—2 2
3—4 17
5—6 9
>7 2
Age groupsa (years) 6—9 1
10—19 3
20—29 4
30—39 7
40—49 5
50 10
Educationa None 6
Primary 9
High school 9
Diploma 6
HEV, hepatitis E virus.
a Some missing data.HEV antibody assay. The presence of anti-HEV in human sera
was determined using a commercial HEV ELISA kit (Dia-pro
from Milan, Italy) according to the manufacturer’s instruc-
tions.
Collected datawere coded, analyzed, and computed using
the Statistical Package for Social Sciences (SPSS) version 13.
Descriptive statistics and Chi-square tests were used in the
statistical analysis, and a p-value of 0.05 was considered
significant.
The study was approved by the Ethics Committee of the
Research Department of Isfahan University of Medical
Sciences.Results
Of the study subjects, 428 were female (52.5%) and 388 were
male (47.5%); 77.7% lived in urban areas and 22.3% in rural
areas. The overall anti-HEV seroprevalence rate was 3.8%.
There was no significant difference between the subjects
grouped according to gender (4.2% in females and 3.4% in
males, p = 0.78) and household number ( p = 0.95). Seropre-
valence increased with age from 0.9% in children aged 6—9
years to 8.1% in persons over 50 years old, but there were no
statistical difference between the age groups ( p = 0.08). No
significant differences were detected between the preva-
lence of anti-HEV antibodies in rural (2.7%) and urban (4.1%)
areas ( p = 0.09) (Table 1). There was also no difference in
anti-HEV seroprevalence according to educational status
( p = 0.5).
When we compared anti-HEV antibody seroprevalence
rates in different regions of Isfahan Province, the highest
prevalences were observed in Khomeini Shahr (13.3%) and
Mobarekeh (10%) (Table 2).sfahan Province (N = 816)
positive Total
(positive + negative)
p-Value
% n %
4.2 428 52.3 0.78
3.4 388 47.7
4.1 634 77.7 0.09
2.7 182 22.3
2.4 85 10.9 0.95
4.2 402 51.7
3.9 230 29.6
3.3 61 7.8
0.9 110 13.9 0.08
2.4 125 15.8
2.2 180 22.7
4.8 145 18.3
4.6 108 13.6
8.1 124 15.7
6.1 98 12.3 0.5
3.2 284 35.5
3.8 236 29.6
3.3 180 22.6
Table 2 Prevalence of anti-HEV according to regions in
Isfahan Province (N = 755)
Region Anti-HEV
positive
Total
(positive + negative)
n % n %
Ardestan 0 0 20 2.6
Borkhar and Meimeh 0 0 42 5.6
Khomeini Shahr 8 13.3 60 7.9
Shahreza 0 0 20 2.6
Dehaghan 0 0 20 2.6
Falavarjan 1 2.1 48 6.4
Golpayegan 0 0 15 2.0
Lenjan 0 0 61 8.1
Mobarekeh 4 10 40 5.3
Najafabad 1 2.5 40 5.3
Tiran and Karvan 0 0 20 2.6
Khansar 0 0 20 2.6
Fereidan 0 0 21 2.8
Fereidunshar 0 0 21 2.8
Natanz 0 0 20 2.6
Isfahan 6 2.1 287 38.0
p-Value <0.001.
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Although several large outbreaks of hepatitis E have been
observed in the Middle East, population-based studies
regarding the seroprevalence of this infection in Iran are
inadequate. In this community-based survey, anti-HEV ser-
oprevalence in Isfahan Province in 2005 has been estimated
at 3.8%. The value obtained is much lower than that of some
of our neighbors, e.g., Iraqi-Kurdish refugees (14.8%)9 and
the general population in Pakistan (17.5%),10 but similar to
rates in Ankara, Turkey (3.8%).11 In Turkey, different results
have been obtained in different regions, and range from 2.1%
to 12.8%.1 In other parts of the world, anti-HEV antibody
seropositivity has been reported at 3.4% in preschool children
in Taiwan,12 10.5% in Mexicans aged 1 to 29 years,13 11.9% in
the Korean population,2 and 17.2% in a village (Nile Delta) in
Egypt.14
In developed countries, HEV seroprevalence is lower. For
example, it has been reported at 2.6% in Italy,15 2.8% in
Israeli Jews, and 1.8% in Israeli Arabs.16 There are limited
documented studies in Iran. In a study by Alizadeh et al.17 in
Nahavand, Iran in 2002, anti-HEV antibody seroprevalence
was 9.6%, and was higher in females and in those aged 30—
50 years than in males and the other age groups. In another
study, anti-HEV antibodies were detected in blood donors in
Tehran, Iran (2004) where the seroprevalence was reported
as 7.8%.18 So, the prevalence of anti-HEV IgG in humans
from this current study is much lower than in previous
studies in other parts of Iran. Also, in this study there
was no statistical relationship between HEV-antibody ser-
opositivity and age, gender, household crowding, or educa-
tion.
These results are consistent with those of most other
studies in the world.19 However, there were different ratesof anti-HEV seropositivity in the different regions of Isfahan
Province, which must be considered for future studies to
obtain the real risk factors in high prevalence areas and to
create preventive strategies.
In conclusion, the prevalence of anti-HEV antibody
in the human population living in Isfahan Province is not
high. More studies are needed in other areas in Iran to
obtain an HEV prevalence map and to limit its transmis-
sion.
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